TABLE 1.

Summary of abdominal transplant recipients who developed SARS‐CoV‐2 infection prior to transplant

	Age/Gender	Transplant type	SARS‐CoV‐2 PCR at transplant (if positive, cycle threshold) †	COVID‐19 to transplant (days)	Antibody testing for SARS‐CoV‐2 result at transplant (IgG/Total)	Repeated PCR (days, result)	Induction immunosuppression	Rejection/Outcome	Follow‐up period
1	37/Female	Liver	Positive, 35.5	90	24.8/88.1	5 and 7 days, negative	High‐dose steroid	No/Survive	190
2	55/Male	Liver/Kidney	Positive, 25	53	10.9/85.5	9 and 20 days, negative	ATG, Basiliximab, Solumedrol	No/Death	86
3	63/Male	Kidney	Positive, 32.5	64	30.9/392	4 days positive, 11 days negative	ATG, Basiliximab, Solumedrol	No/Survive	129
4	66/Male	Kidney	Positive, 35.2	60	5.8/104	6 and 10 days, negative	ATG, Basiliximab, Solumedrol	No/Survive	24
5	65/Male	Liver/Kidney	Negative	61	0.13/4.9	9 days positive, 35 days negative	ATG, Basiliximab, Solumedrol	No/Survive	105
6	66/Female	Liver	Negative	202	22/97.1	8 and 14 days, negative	High‐dose steroid	Yes/Survive	100
7	50/Male	Liver	Negative	165	8.1/260	11 days, negative	High‐dose steroid	No/Survive	39
8	51/Male	Liver	Negative	107	2.1/36	10 days, negative	High‐dose steroid	No/Survive	46
9	55/Male	Kidney	Negative	61	31/856	14 days, negative	ATG, Basiliximab, Solumedrol	No/Survive	113
10	31/Male	Kidney	Negative	113	12.9/106	14 days, negative	ATG, Basiliximab, Solumedrol	No/Survive	135
11	65/Male	Kidney	Negative	113	29/482	7 days, negative	ATG, Basiliximab, Solumedrol	No/Survive	68
12	56/Male	Kidney	Negative	147	8.0/220	32 days, negative	ATG, Basiliximab, Solumedrol	No/Survive	41
13	30/Male	Kidney	Negative	149	0.02/0.68	4 days, negative	ATG, Basiliximab, Solumedrol	No/Survive	72
14	43/Female	Kidney(Living donor)	Negative	172	0.23/19.7	3 and 16 days, negative	ATG, Basiliximab, Solumedrol, Rituximab	No/Survive	22

Abbreviations: SARS‐CoV‐2, Severe Acute Respiratory Syndrome Coronavirus 2: PCR, polymerase chain reaction: ATG, anti‐thymocyte globulin.

^† PCR platform: Cepheid